Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding its clinical-stage oncology business. As a Delaware corporation listed on Nasdaq, Lixte files a range of documents with the U.S. Securities and Exchange Commission that detail its drug development activities, capital structure, and corporate governance.
Core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) typically describe Lixte’s focus on PP2A inhibitor cancer therapies, led by its clinical compound LB-100, and outline risks and operational considerations associated with its clinical-stage status. The company’s proxy statements on Form DEF 14A provide information on board composition, stockholder proposals, stock incentive plans, and auditor ratification, as illustrated by the definitive proxy statement describing its 2025 annual meeting.
Lixte’s current reports on Form 8-K are particularly important for tracking material events. For example, an 8-K dated November 25, 2025, describes a Share Exchange Agreement through which Lixte acquired all shares of Liora Technologies Europe Ltd., gaining proton therapy assets associated with the LIGHT (Linac Guided Hadron Therapy) system. The same filing outlines the creation of Series C Convertible Preferred Stock and a Royalty Agreement that entitles the seller to a percentage of Net Revenue from the acquired equipment up to a specified cap.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key terms, such as transaction structures, royalty obligations, and equity issuances, helping readers quickly interpret complex documents. Users can review real-time updates from EDGAR, examine details of offerings and preferred stock designations, and connect these disclosures to Lixte’s broader strategy of building a multi-asset oncology platform.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
Lixte Biotechnology Holdings (LIXT) completed a share exchange to acquire all shares of Liora Technologies Europe Ltd., which owns the LIGHT proton-based radiotherapy assets previously acquired from Advanced Oncotherapy. As consideration, Lixte will issue 2,700 shares of Series C Preferred Stock, convertible into 2,700,000 common shares (subject to a 19.99% cap until shareholder approval), pay 10.56 Bitcoin, 300 Ethereum, and $440,000 in cash, and enter a royalty agreement. The royalty entitles the seller to 10% of Net Revenue from the LIGHT equipment, up to a $45,000,000 cap, with quarterly calculations and audit rights. The new Series C Preferred Stock is non‑voting, non‑dividend bearing, convertible at a 1,000:1 ratio into common stock, and carries ownership limits tied to Nasdaq shareholder approval requirements.
Lixte Biotechnology Holdings (LIXT) filed its Q3 2025 10‑Q, reporting a net loss of $1,980,398 for the quarter and $3,465,626 for the nine months. The quarter reflected $50,696 in research and development and $1,750,658 in general and administrative costs, with a basic and diluted net loss per share of $0.33.
As of September 30, 2025, cash was $2,887,874. The company held digital assets (Bitcoin and Ethereum) of $2,454,473 at fair value and recorded an unrealized loss of $182,887. Lixte completed equity financings in July 2025, including a $5.05 million private placement and a $1.5 million registered direct offering, and subsequently regained Nasdaq stockholders’ equity compliance on July 15, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, while estimating existing cash supports operations for at least 12 months from quarter-end. Shares outstanding were 5,704,200 as of November 5, 2025.
Lixte Biotechnology Holdings, Inc. called its 2025 Annual Meeting to vote on three items: elect five directors, ratify Weinberg & Company, P.A. as auditor, and amend the 2020 Stock Incentive Plan to increase shares issuable by 2,750,000 to a total of 3,500,000 shares.
The virtual meeting is on December 8, 2025 at 1:00 p.m. ET. The record date is October 14, 2025, when 5,704,200 common shares were outstanding and entitled to vote. Director nominees are Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix and Guy Primus. The board recommends voting “FOR” all proposals.
As context, under the 2020 Plan, unexpired stock options for 694,309 shares were outstanding and 55,691 shares remained available as of September 30, 2025. The company reports a three‑year average net burn rate of 6.1%. For audit services, fees billed to Weinberg totaled $143,618 in 2024.